Client Work Detail
matter
Enobia Completes Third Tranche of its $40.1M Private Financing
CLIENT
Enobia Pharma Inc.
DATE
August 15, 2008
LAWYER(S)
On August 15, 2008, Enobia Pharma, a biopharmaceutical company developing therapeutics for the treatment of severe orphan disorders affecting the bone, completed the third tranche of its $40.1 million private financing, the first tranche of which was initially completed on August 30, 2007. Enobia Pharma Corp. received $13 million on the closing of this third tranche. The financing was co-led by Orbimed Advisors LLC of New York and CTI Life Sciences Fund, LP of Montreal. Additional participants in the financing included existing investors Desjardins Venture Capital, Fonds de solidarité des travailleurs du Québec (F.T.Q.), T2C2/Bio 2000, Société en commandite and Lothian Partners (sarl) Sicar.
Enobia Pharma was represented by Gino Martel and Elliot Shapiro of Ogilvy Renault LLP.
